3-chloro-5-cyclopropyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxylic acid | 1297137-35-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 3-chloro-5-cyclopropyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxylic acid
• CAS: 1297137-35-9
• 化学式: C₁₂H₈ClF₃N₂O₂
• 分子量: 304.656
• InChiKey: VMDXCOHTOLTOJS-UHFFFAOYSA-N

物化性质

• 密度：
  1.75±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-chloro-5-cyclopropyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxylic acid 在 硫酸 aluminum tri-bromide 、 硫酸 、 水 、 potassium carbonate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 乙硫醇 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 92.0h， 生成 5-羟基-7-(三氟甲基)吡唑并[1,5-a]吡啶-2-羧酸甲酯
  参考文献：
  名称：

  [EN] PYRAZOLYLPYRIDINE ANTIVIRAL AGENTS
  [FR] AGENTS ANTIVIRAUX DE PYRAZOLYLPYRIDINE

  摘要：

  提供的是公式(I)和/或公式(II)的化合物以及它们的药用可接受的盐、它们的药物组合物、它们的制备方法，以及它们用于治疗由黄病毒科病毒家族成员如丙型肝炎病毒(HCV)介导的病毒感染。

  公开号：

  WO2011050284A1
• 作为产物：
  描述：

  2-三氟甲基吡啶 在 盐酸 、 甲醇 、 potassium phosphate 、 N-氯代丁二酰亚胺 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 (1,5-cyclooctadiene)(methoxy)iridium(I) dimer 、 硫酸 、 双氧水 、 potassium carbonate 、 溶剂黄146 、 N,N-二异丙基乙胺 、 4,4'-二叔丁基-2,2'-二吡啶 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 150.3h， 生成 3-chloro-5-cyclopropyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxylic acid
  参考文献：
  名称：

  Hepatitis C Replication Inhibitors That Target the Viral NS4B Protein

  摘要：

  We describe the preclinical development and in vivo efficacy of a novel chemical series that inhibits hepatitis C virus replication via direct interaction with the viral nonstructural protein 4B (NS4B). Significant potency improvements were realized through isosteric modifications to our initial lead la. The temptation to improve antiviral activity while compromising physicochemical properties was tempered by the judicial use of ligand efficiency indices during lead optimization. In this manner, compound la was transformed into (+)-28a which possessed an improved antiviral profile with no increase in molecular weight and only a modest elevation in lipophilicity. Additionally, we employed a chimeric "humanized" mouse model of HCV infection to demonstrate for the first time that a small molecule with high in vitro affinity for NS4B can inhibit viral replication in vivo. This successful proof-of-concept study suggests that drugs targeting NS4B may represent a viable treatment option for curing HCV infection.

  DOI：

  10.1021/jm400125h

文献信息

• 作为NS4B抑制剂的苯并呋喃类似物
  申请人：常州寅盛药业有限公司

  公开号：CN105732602B

  公开（公告）日：2017-04-19

  本发明公开了一类作为NS4B抑制剂的苯并呋喃类似物，具体公开了式(I)所示化合物或其药学上可接受的盐。
• BENZOFURAN ANALOGUE AS NS4B INHIBITOR
  申请人：Changzhou Yinsheng Pharmaceutical Co., Ltd.

  公开号：EP3199530A1

  公开（公告）日：2017-08-02

  Provided is a benzofuran analogue having a structure represented by formula (I) and used as an NS4B inhibitor, or a pharmaceutically acceptable salt of the benzofuran analogue. The benzofuran analogue has anti-hepatitis C virus activity.

  本研究提供了一种具有式（I）所代表的结构并用作 NS4B 抑制剂的苯并呋喃类似物，或该苯并呋喃类似物的药学上可接受的盐。该苯并呋喃类似物具有抗丙型肝炎病毒的活性。
• Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein
  作者：Vincent W.-F. Tai、Dulce Garrido、Daniel J. Price、Andrew Maynard、Jeffrey J. Pouliot、Zhiping Xiong、John W. Seal、Katrina L. Creech、Luz H. Kryn、Todd M. Baughman、Andrew J. Peat

  DOI：10.1016/j.bmcl.2014.03.080

  日期：2014.5

  Two novel series of spirocyclic piperidine analogs appended to a pyrazolo[1,5-alpha] pyridine core were designed, synthesized and evaluated for their anti-HCV activity. A series of piperidine ketals afforded dispiro 6p which showed excellent in vitro anti-HCV activities (EC50 of 1.5 nM and 1.2 nM against genotype 1a and 1b replicons, respectively). A series of piperidine oxazolidinones afforded 27c which showed EC50's of 10.9 nM and 6.1 nM against 1a and 1b replicons, respectively. Both compounds 6p and 27c bound directly to non-structural NS4B protein in vitro (IC50's = 10.2 and 30.4 nM, respectively) and exhibited reduced potency in replicons containing resistance mutations encoding changes in the NS4B protein. (C) 2014 Elsevier Ltd. All rights reserved.
• Hepatitis C Replication Inhibitors That Target the Viral NS4B Protein
  作者：John F. Miller、Pek Y. Chong、J. Brad Shotwell、John G. Catalano、Vincent W.-F. Tai、Jing Fang、Anna L. Banka、Christopher D. Roberts、Michael Youngman、Huichang Zhang、Zhiping Xiong、Amanda Mathis、Jeffery J. Pouliot、Robert K. Hamatake、Daniel J. Price、John W. Seal、Lisa L. Stroup、Katrina L. Creech、Luz H. Carballo、Dan Todd、Andrew Spaltenstein、Sylvia Furst、Zhi Hong、Andrew J. Peat

  DOI：10.1021/jm400125h

  日期：2014.3.13

  We describe the preclinical development and in vivo efficacy of a novel chemical series that inhibits hepatitis C virus replication via direct interaction with the viral nonstructural protein 4B (NS4B). Significant potency improvements were realized through isosteric modifications to our initial lead la. The temptation to improve antiviral activity while compromising physicochemical properties was tempered by the judicial use of ligand efficiency indices during lead optimization. In this manner, compound la was transformed into (+)-28a which possessed an improved antiviral profile with no increase in molecular weight and only a modest elevation in lipophilicity. Additionally, we employed a chimeric "humanized" mouse model of HCV infection to demonstrate for the first time that a small molecule with high in vitro affinity for NS4B can inhibit viral replication in vivo. This successful proof-of-concept study suggests that drugs targeting NS4B may represent a viable treatment option for curing HCV infection.
• [EN] PYRAZOLYLPYRIDINE ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DE PYRAZOLYLPYRIDINE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011050284A1

  公开（公告）日：2011-04-28

  Provided are compounds of Formula (I) and/or Formula (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

  提供的是公式(I)和/或公式(II)的化合物以及它们的药用可接受的盐、它们的药物组合物、它们的制备方法，以及它们用于治疗由黄病毒科病毒家族成员如丙型肝炎病毒(HCV)介导的病毒感染。